Plague vaccine intranasal - ID Biomedical/USAMRMC

Drug Profile

Plague vaccine intranasal - ID Biomedical/USAMRMC

Alternative Names: Yersinia pestis vaccine intranasal - ID Biomedical/USAMRMC

Latest Information Update: 27 Jun 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ID Biomedical Corporation; United States Army Medical Research and Materiel Command
  • Class Plague vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pneumonic plague

Most Recent Events

  • 27 Jun 2007 Discontinued - Preclinical for Pneumonic plague in USA (Intranasal)
  • 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
  • 23 Sep 2004 ID Biomedical was awarded up to US$8 million from the US NIH to develop a nasally delivered plague vaccine based upon the ID Biomedical's Proteosome™ technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top